|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 4 (February 15), 2000:
pp. 1342-1349
Stimulation of cytotoxic T cells against idiotype immunoglobulin
of malignant lymphoma with protein-pulsed or idiotype-transduced
dendritic cells
Frank Osterroth,
Annette Garbe,
Paul Fisch, and
Hendrik Veelken
From the Departments of Hematology/Oncology and Pathology, Freiburg
University Medical Center; the Department of Biology, Freiburg
University; and Cellgenix GmbH, Freiburg, Germany.
Because of their hypervariable regions and somatic mutations, the
antigen receptor molecules of lymphomas (idiotypes) are tumor-specific antigens and attractive targets for antilymphoma immunotherapy. For the optimal induction of human idiotype-specific cytotoxic T cells (CTL), idiotype was presented to
CD8+ peripheral blood mononuclear cells by
monocyte-derived autologous dendritic cells (DC) after the endocytosis
of idiotype protein or by idiotype-expressing DC. Recombinant
idiotype was obtained as a functionally folded Fab fragment by
periplasmic expression in Escherichia coli. Idiotype-expressing
DC were generated by transduction with recombinant Semliki forest virus
vectors encompassing heavy- or light-chain idiotype genes.
Autologous lymphoblastoid cell lines stably transfected with
Epstein-Barr virus-based idiotype expression vectors were used as
target cells to detect idiotype-specific lysis. CTL stimulated with
idiotype-loaded DC showed strong specific, CD8-mediated, and major
histocompatibility complex (MHC) class I-restricted cytotoxicity
against autologous heavy- and light-chain idiotype. In contrast,
stimulation with idiotype-transduced DC resulted in only moderate
natural killer cell activity. These data confirm the existence of
idiotype-specific CTL in patients with lymphoma, define a "good
manufacturing practice"-compatible protocol for the generation of
these cells without the requirement of viable lymphoma cells, and favor
the processing of exogenous antigen over DC transduction for the
induction of MHC I-restricted CTL against idiotypes with unknown antigenicity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W.-K. Weng, D. Czerwinski, and R. Levy
Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy
Blood,
February 1, 2007;
109(3):
951 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bertinetti, K. Zirlik, K. Heining-Mikesch, G. Ihorst, H. Dierbach, C. F. Waller, and H. Veelken
Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Cancer Res.,
April 15, 2006;
66(8):
4496 - 4502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Muraro, A. Bondanza, M. Bellone, P. D. Greenberg, and C. Bonini
Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses
Blood,
May 1, 2005;
105(9):
3596 - 3604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Armstrong, S. Dermime, C. G. Allinson, T. Bhattacharyya, K. Mulryan, K. R. Gonzalez, P. L. Stern, and R. E. Hawkins
Immunization with a Recombinant Adenovirus Encoding a Lymphoma Idiotype: Induction of Tumor-Protective Immunity and Identification of an Idiotype-Specific T Cell Epitope
J. Immunol.,
April 15, 2002;
168(8):
3983 - 3991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Timmerman, D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al.
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients
Blood,
March 1, 2002;
99(5):
1517 - 1526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology,
January 1, 2002;
2002(1):
241 - 262.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Harig, M. Witzens, A. M. Krackhardt, A. Trojan, P. Barrett, R. Broderick, A. J. Zauls, and J. G. Gribben
Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues
Blood,
November 15, 2001;
98(10):
2999 - 3005.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy
Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas
Blood,
March 1, 2001;
97(5):
1370 - 1377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology,
January 1, 2001;
2001(1):
221 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Eichmuller, D. Usener, R. Dummer, A. Stein, D. Thiel, and D. Schadendorf
Serological detection of cutaneous T-cell lymphoma-associated antigens
PNAS,
January 16, 2001;
98(2):
629 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
